Skip to content
Evigrade
ModerateXanthine oxidase inhibitors×Triple fixed-dose combination: dopamine precursor, peripheral decarboxylase inhibitor, and COMT inhibitor

Updated · Methodology

Mechanism

Xanthine oxidase and aldehyde oxidase convert allopurinol to active oxipurinol, which the kidneys excrete. Allopurinol is barely bound to plasma proteins (Zyloric SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Levodopa is broken down mainly by dopa decarboxylase and catechol-O-methyltransferase, carbidopa is excreted in urine, and entacapone is glucuronidated and excreted mainly in bile (Stalevo SmPC, European Medicines Agency, EMA). Their metabolic pathways do not overlap, and the interaction sections of neither drug mention the other (Zyloric SmPC, AEMPS, and Stalevo SmPC, EMA). The shared point is drowsiness. The US label of the combination advises asking about sedating medications, which increase the risk of drowsiness and sudden sleep onset, before treatment starts. The US allopurinol label states that its central nervous system depressant effects may add to those of alcohol and other CNS depressants (carbidopa-levodopa-entacapone and allopurinol labels, US Food and Drug Administration, FDA).

Symptoms

The documents describe no symptoms specific to this combination, but both drugs can cause drowsiness and dizziness, and drowsiness may be stronger when they are taken together (carbidopa-levodopa-entacapone and allopurinol labels, US Food and Drug Administration, FDA). Carbidopa, levodopa and entacapone cause drowsiness and sudden sleep onset during daily activities, including driving and without prior sleepiness, sometimes up to a year after the start of treatment. The combination can also cause orthostatic hypotension, dyskinesia and hallucinations (carbidopa, levodopa and entacapone label, FDA). Allopurinol very rarely causes drowsiness, vertigo and ataxia, and its main risk is serious skin and hypersensitivity reactions (Zyloric SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

No document names the pair, but by its own documents allopurinol can cause drowsiness and has central nervous system depressant effects (Zyloric SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and allopurinol label, US Food and Drug Administration, FDA). Before starting carbidopa, levodopa and entacapone, ask about factors that increase the risk of drowsiness, including the use of sedating medications (carbidopa, levodopa and entacapone label, FDA). According to the documents, doses are not changed in advance. If daytime sleepiness or episodes of falling asleep during activities that require active participation occur, carbidopa, levodopa and entacapone should ordinarily be discontinued. If treatment continues, driving and other potentially dangerous activities are not advised (carbidopa, levodopa and entacapone label, FDA, and Stalevo SmPC, European Medicines Agency, EMA). People should not drive or operate machinery until they are reasonably sure that allopurinol does not affect their performance (Zyloric SmPC, AEMPS). When allopurinol is started or its dose is increased, they are told that its CNS depressant effects may add to those of alcohol and other CNS depressants (allopurinol label, FDA). During long-term treatment with carbidopa, levodopa and entacapone, hepatic, haematopoietic, cardiovascular and renal function are assessed periodically, and a lower allopurinol dose is considered in hepatic or renal impairment (Stalevo SmPC, EMA, and Zyloric SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Allopurinol

Other interactions with Levodopa + Carbidopa + Entacapone